Announcement on Subsidiary’s Drug Entering Key Clinical Trials
Filed with SSE · · 3 pages · Chinese
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited on 6ix
Earlier from Guangzhou Baiyunshan Pharmaceutical
- Notice on Convening the 2nd Extraordinary General Meeting in 2025
- Announcement on Subsidiary Obtaining Approval for Marketing of Chemical APIs
- Announcement on Convening the 2025 Semi-annual Performance Briefing
- Announcement on the Completion of Private Fund Filing and Progress of Related Party Transactions
- Full Text of 2025 Semi-annual Report
Later from Guangzhou Baiyunshan Pharmaceutical
- Announcement on Subsidiary’s Drug Entering Phase II Clinical Trials
- Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2025
- Announcement on Resolutions of the 29th Meeting of the 9th Board of Directors
- Announcement on Subsidiary’s Drug Entering Phase III Clinical Trials
- Report for Q3 2025
Follow Guangzhou Baiyunshan Pharmaceutical into a list and get an email when it puts out news.
Follow Guangzhou Baiyunshan Pharmaceutical